Amnavero.
← Research directory

Research profile

Tesamorelin

Tesamorelin stimulates growth hormone release. An approved U.S. prescription formulation is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy.

  • Randomized clinical trial
  • Evaluation only
Amnavero Tesamorelin research vial concept packaging
Amnavero Tesamorelin
Concept packaging

What the research found

In a randomized trial of 404 people with HIV and excess abdominal fat, visceral fat fell by 10.9% with tesamorelin and 0.6% with placebo over six months.

What remains uncertain

The trial focused on visceral fat in a specific population. The prescription label defines the indication and addresses risks such as elevated blood sugar.